IL6 and familial pancreatic carcinoma: This study explored the correlation between pretreatment serum IL-6 levels, encompassing pro-inflammatory cytokine levels, and survival outcomes in advanced pancreatic cancer patients, while also assessing how these biomarkers influence the efficacy of systemic chemotherapy.